October 6, 2017 / 7:07 PM / 2 years ago

Flexion's knee pain drug gets FDA nod

Oct 6 (Reuters) - Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain.

The approval came at a time when federal authorities in the United States are implementing a slew of measures to cut down the supply of opioid painkillers amid their continuous abuse, with President Donald Trump in August declaring the opioid epidemic a national emergency.

Osteoarthritis knee pain is a degenerative joint disease that affected more than 14 million Americans in 2015.

Reporting by Divya Grover and Tamara Mathias in Bengaluru; Editing by Martina D'Couto

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below